Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Catalyst Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CPRX
Nasdaq
2834
https://catalystpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
- Apr 22nd, 2024 12:00 pm
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is largely controlled by institutional shareholders who own 65% of the company
- Apr 18th, 2024 2:49 pm
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024
- Apr 13th, 2024 4:18 pm
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
- Mar 29th, 2024 3:30 pm
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
- Mar 28th, 2024 12:03 pm
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
- Mar 27th, 2024 12:03 pm
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
- Mar 27th, 2024 11:44 am
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have seen strong returns of 271% over the past three years
- Mar 22nd, 2024 2:00 pm
Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?
- Mar 20th, 2024 9:14 am
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
- Mar 19th, 2024 12:01 am
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
- Mar 13th, 2024 11:55 am
3 Sexy Small-Cap Stocks to Add Sizzle to Your Portfolio
- Mar 10th, 2024 7:24 pm
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
- Mar 5th, 2024 1:03 pm
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
- Feb 29th, 2024 12:20 am
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Feb 28th, 2024 11:03 pm
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
- Feb 27th, 2024 1:03 pm
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
- Feb 21st, 2024 2:00 pm
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
- Feb 14th, 2024 1:03 pm
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
- Jan 18th, 2024 2:50 pm
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances
- Jan 18th, 2024 9:54 am
Scroll